Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDS to begin study of CT laser mammography system under conditional IDE.

This article was originally published in The Gray Sheet

Executive Summary

IMAGING DIAGNOSTIC SYSTEMS' PAINLESS MAMMOGRAM TRIALS SET TO COMMENCE Feb. 28 at the Strax Breast Cancer Institute in Fort Lauderdale, Florida, the company says. On Feb. 13, FDA granted IDS a conditional investigational device exemption that allows preliminary clinical trials to begin with 50 patients. The trials are designed to show that IDS' Computed Tomography Laser Mammography (CTLM) technology, performed on the firm's proprietary scanning table, is a safe and effective diagnostic tool for breast cancer.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel